Navigation Links
Genetic testing may be used to identify BPH patients with increased risk of prostate cancer
Date:3/19/2013

Milan, 19 March 2013 Patients with benign prostatic hyperplasia (BPH) carrying prostate cancer (PCa) a risk alleles are a potential target population for PCa screening and follow-up, according to a study, which was presented yesterday at the 28th Annual EAU Congress in Milan.

The study aimed to evaluate the genetic predisposition of patients with BPH to developing prostate cancer, with findings suggesting that genetic testing may offer a new tool to identify BPH patients with increased risk to develop PrCa.

"To our knowledge this is the first study to evaluate genetic predisposition in BPH patients developing PrCa," write the authors.

Benign prostatic hyperplasia and prostate cancer are common diseases affecting the prostate gland in aging men. Although BPH often explains the increase of PSA, the patients with elevated PSA often develop prostate cancer in follow-up after initial benign histology in prostate biopsy.

The researchers were looking to find new potential tools which would help to identify patients with elevated PCa risk among those who undergo biopsy due to rCa suspicion but have histologically confirmed BPH and no PCa in baseline biopsy.

We investigated whether the single nucleotide polymorphisms (SNP) previously found to be associated to genetic predisposition to PCa could also be used for evaluation of PCa risk in BPH patients.

In the course of the study 262 patients diagnosed with histologically confirmed BPH and 254 patients originally diagnosed with BPH and later developing PCa were analysed. These patients were originally examined due to elevated PSA or abnormal digital rectal examination and underwent prostate biopsy confirming BPH in Tampere University Hospital, Findland, between 1995 and 2004.

The follow-up time was from 7 to 16 years. The patients diagnosed with PCa within one year after original diagnosis of BPH were not included. The PCa diagnoses were confirmed from the patient records and from the Finnish Cancer Registry and 100 single nucleotide polymorfism (SNP) markers previously linked to the PCa risk were genotyped.

Ten markers showed statistically significant association to PCa risk (OR > 1.4, p<0.05). Marker RS138213197 (HOXB13), which has previously been linked to the familial PCa, showed the strongest association to PCa.

BPH patients carrying this mutation had 4.6 times higher risk of developing PCa compared to non-carriers (OR 4.56, CI 95% 1.29 - 16.11, p=0,0098). The average PSA levels at baseline biopsy in BPH and PCa groups were 7.3 μg/l (range 0.5-44 μg/l) and 8.0 μg/l (range 2.1 75 μg/l) respectively.


'/>"/>

Contact: Ivanka Moerkerken
i.moerkerken@uroweb.org
31-026-389-0680
European Association of Urology
Source:Eurekalert

Related medicine news :

1. IntegraGen launches ARISk test, a genetic screening tool for autism in high-risk children
2. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
3. Head, Body Lice Are Genetically Very Similar
4. Certain Genetic Regions May Be Tied to Osteoporosis
5. Study of half siblings provides genetic clues to autism
6. Genetic variants, tobacco exposure and lung cancer risk
7. Research Gets Closer to Genetic Roots of Glaucoma
8. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
9. Genetically modified T cell therapy shown to be safe, lasting in decade-long study of HIV patients
10. Some women may be genetically predisposed to smoking-related hot flashes
11. Genetic abnormalities in benign or malignant tissues predict relapse of prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... Mediaplanet today announces distribution of ... while encouraging readers to sign up as an organ donor for the 123,000 people ... , An organ donor can save up to 8 saves through organ donation and ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time trying to ... "I thought that if the nebulizer had a more child-friendly design, then children would ... He developed the patent-pending NEBY to avoid the need to deliver medication via a ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... with distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority ... care and patient safety. Only a few hospitals and facilities have earned this ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... “Natural Language Processing–Enabled and Conventional Data Capture Methods for Input to Electronic Health ... . , Results of the comparative usability study demonstrate that a dictation-based method ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s ... groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced ... J. Hennessy, Jr said, “CURE Media Group is honored to team up with Upstage ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) has ... 2016 Top Workplaces National Standard. To learn ... ... (PRNewsFoto/Diplomat Pharmacy, Inc.) ... an employee survey administered by WorkplaceDynamics, LLC, a research firm specializing ...
(Date:12/8/2016)...  Eli Lilly and Company (NYSE: LLY ... EXPEDITION3 trial at the 9 th Clinical Trials ... did not meet the primary endpoint in the EXPEDITION3 ... with mild dementia due to Alzheimer,s disease (AD), and ... the treatment of mild dementia due to AD. ...
(Date:12/8/2016)... Research and Markets has announced the addition of the "Global ... - Forecast to 2025" report to their offering. ... , , ... a CAGR of around 3.2% from 2015 to 2025. Some of ... extracellular microelectrode arrays and intracellular microelectrodes, research in left-to-right shunt detection ...
Breaking Medicine Technology: